CI 1021

Drug Profile

CI 1021

Alternative Names: PD 154075

Latest Information Update: 22 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Analgesics; Antiemetics; Benzofurans
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Nausea and vomiting; Pain

Most Recent Events

  • 22 Feb 2006 No development reported - Preclinical for Pain in USA (unspecified route)
  • 19 Jun 2001 No-Development-Reported for Emesis (Unknown route)
  • 22 Mar 2001 CI 1021 is being investigated for use in Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top